Clinical Trials and Research Studies
Phase 2
A Phase 2 Study of REGN2810 a Fully Human Monoclonal Antibody to Programmed Death-1 in Patients with Advanced Basal Cell Carcinoma who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy or were Intolerant of Prior Hedgehog Pathway Inhibitor therapy
Learn MorePhase 1
A Phase 1 b Study of the Selective HDAC Inhibitor Mocetinostat in Combination with Ipilimumab and Nivolumab in Patients with Unresectable Stage III or Stage IV Melanoma
Learn MorePhase 3
A randomized double-blind placebo-controlled phase III study comparing the combination of PDR001 dabrafenib and trametinib versus placebo dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600 mutant melanoma
Learn MorePhase 2
A Phase 2 Multicenter Single-arm Study to Assess the Safety Feasibility and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-144) Followed by IL-2 for Treatment of Metastatic Melanoma
Learn More